TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Net Income

Bottom-line profit after all expenses, interest, and taxes.

TerrAscend Corp.TSX: TSND.TO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$8.91M, compared with -$13.57M a year earlier. Trailing-twelve-month net income was -$81.53M.

Context

  • Net income amounted to 33.1% of revenue in FY2025, up 6.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$20.37M (+76.8%) for the fiscal year ending Dec 2026, a step up from the -9.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.91M-453.0% QoQ
Last fiscal yearDec 2025
-$87.74M-9.4% YoY
LTMMar 2026
-$81.53M-6.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.3%+93.7%+59.4 pp
1 year-9.4%+76.8%+86.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(87.74M) USD
Year-over-year change
-9.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.2% is the 6th highest of 10, against a peer median of +39.0%.
  • Net income amounts to 31.2% of revenue for TSND.TO, versus a peer median of 17.8%.
TSND.TO Competitors
Net Income for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$33.21M CAD+52.5%—20.9%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$30.97M USD+235.0%+1.4%60.8%
DR.TOMedical Facilities CorporationLTM Mar 2026$25.98M USD-65.6%—8.5%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-$8.81M USD+39.0%—17.2%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026-$10.27M USD+42.9%—18.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$25.21M CAD-249.3%—9.2%
ACB.TOAurora Cannabis Inc.LTM Mar 2026-CA$38.62M CAD-2527.2%—12.1%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$42.19M USD-100.7%——
TSND.TOTerrAscend Corp.LTM Mar 2026-$81.53M USD-6.2%—31.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$263.55M CAD+55.9%—84.8%
Peer median (excluding TSND.TO) —+39.0%+1.4%17.8%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.36M240.45M317.33M306.68M265.12M
Cost of Revenue109.32M203.35M112.49M156.72M131.93M
Gross Profit134.04M119.74M138.02M149.96M133.19M
Gross Margin55.1%49.8%43.5%48.9%50.2%
Research & Development00000
Selling, General & Admin73.71M116.64M112.17M111.33M82.41M
Operating Expenses94.12M150.69M179.56M167.07M87.78M
Depreciation & Amortization13.63M24.6M22.7M22.99M17.51M
EBITDA44.96M(246.52M)(1.03M)6.16M62.92M
EBITDA Margin18.5%-102.5%-0.3%2.0%23.7%
Operating Income31.33M(23.04M)(19.87M)(17.11M)45.41M
Operating Margin12.9%-9.6%-6.3%-5.6%17.1%
Interest Income00000
Interest Expense24.57M37.9M35.11M35.4M36.93M
Other Income / Expenses12.46M(277.92M)(38.97M)(35.13M)(40.34M)
Income Before Tax43.78M(300.95M)(58.83M)(52.23M)5.06M
Pre-Tax Margin18.0%-125.2%-18.5%-17.0%1.9%
Income Tax Expense28.88M(10.46M)23.45M20.44M29.98M
Net Income3.06M(303.96M)(91.1M)(80.23M)(87.74M)
Net Margin1.3%-126.4%-28.7%-26.2%-33.1%
EPS (Basic)0.07(1.31)(0.32)(0.28)(0.29)
EPS (Diluted)0.01(1.31)(0.32)(0.28)(0.29)
Weighted Avg Shares181.06M244.35M279.29M291.51M301.08M
Weighted Avg Shares (Diluted)208.71M244.35M279.29M291.51M301.08M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.